Chemo, immunotherapy, and radiation for stomach cancer before surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of chemotherapy (FLOT), an immunotherapy drug (pembrolizumab), and short-course radiation before surgery for gastroesophageal junction cancer. The goal is to see if this approach improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have adenocarcinoma of the gastroesophageal junction (where the stomach meets the esophagus).
- You have not received any chemotherapy or radiation for this cancer before.
- Your cancer is locally advanced but has not spread to other organs (stages T2-4, any N, M0).
- You are 18 or older and in good general health (ECOG 0 or 1).
- Your blood counts and kidney/liver function are within normal limits (specific lab thresholds apply).
- You are not pregnant and agree to use effective contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining chemotherapy (SOX), an immunotherapy drug (tislelizumab), and low-dose radiation before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination shrinks tumors more effectively.
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy to shrink gastroesophageal junction cancer before surgery. It aims to make the tumor removable and improve outcomes.
This trial tests a combination of shortened radiation therapy, immunotherapy, and chemotherapy given before surgery for cancer at the junction of the esophagus and stomach. The goal is to see if this approach is safe and improves outcomes.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
This trial tests combining chemotherapy, immunotherapy, and radiation before surgery for stomach or gastroesophageal junction cancer that has spread to a limited number of sites. The goal is to see if this approach can improve outcomes by shrinking tumors before they are removed.
Hear when a new Gastroesophageal Junction (GEJ) Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.